Mapping	O
cell	O
type	O
-	O
specific	O
transcriptional	O
enhancers	O
using	O
high	O
affinity	O
,	O
lineage	O
-	O
specific	O
Ep300	O
bioChIP	O
-	O
seq	O
.	O


Understanding	O
the	O
mechanisms	O
that	O
regulate	O
cell	O
type	O
-	O
specific	O
transcriptional	O
programs	O
requires	O
developing	O
a	O
lexicon	O
of	O
their	O
genomic	O
regulatory	O
elements	O
.	O


We	O
developed	O
a	O
lineage	O
-	O
selective	O
method	O
to	O
map	O
transcriptional	O
enhancers	O
,	O
regulatory	O
genomic	O
regions	O
that	O
activate	O
transcription	O
,	O
in	O
mice	O
.	O


Since	O
most	O
tissue	O
-	O
specific	O
enhancers	O
are	O
bound	O
by	O
the	O
transcriptional	O
co	O
-	O
activator	O
Ep300	O
,	O
we	O
used	O
Cre	O
-	O
directed	O
,	O
lineage	O
-	O
specific	O
Ep300	O
biotinylation	O
and	O
pulldown	O
on	O
immobilized	O
streptavidin	O
followed	O
by	O
next	O
generation	O
sequencing	O
of	O
co	O
-	O
precipitated	O
DNA	O
to	O
identify	O
lineage	O
-	O
specific	O
enhancers	O
.	O


By	O
driving	O
this	O
system	O
with	O
lineage	O
-	O
specific	O
Cre	O
transgenes	O
,	O
we	O
mapped	O
enhancers	O
active	O
in	O
embryonic	B-TISSUE
endothelial	I-TISSUE
cells	E-TISSUE
/	O
blood	S-TISSUE
or	O
skeletal	B-TISSUE
muscle	E-TISSUE
.	O


Analysis	O
of	O
these	O
enhancers	O
identified	O
new	O
transcription	O
factor	O
heterodimer	O
motifs	O
that	O
likely	O
regulate	O
transcription	O
in	O
these	O
lineages	O
.	O


Furthermore	O
,	O
we	O
identified	O
candidate	O
enhancers	O
that	O
regulate	O
adult	O
heart	S-TISSUE
-	O
or	O
lung	S-TISSUE
-	O
specific	O
endothelial	B-TISSUE
cell	E-TISSUE
specialization	O
.	O


Our	O
strategy	O
for	O
tissue	O
-	O
specific	O
protein	O
biotinylation	O
opens	O
new	O
avenues	O
for	O
studying	O
lineage	O
-	O
specific	O
protein	O
-	O
DNA	O
and	O
protein	O
-	O
protein	O
interactions	O
.	O
